Genetic Testing Services

Natera Announces Pricing of Follow-On Offering | PR Newswire | 9/11/2020

… a focus on women’s health, oncology, and organ health. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. Forward-looking Statements Except for historical information, certain statements in this press …

Natera’s Signatera™ MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer | PR Newswire | 9/11/2020

… on women’s health, oncology, and organ health. Natera operates ISO 13485-certified and CAP-accredited labs certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California , and Austin, Texas . It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com . Follow Natera on LinkedIn . About Signatera Signatera …

Follow Genetic Testing Services:    

Natera Launches Proposed Follow-On Offering | PR Newswire | 9/10/2020

… a focus on women’s health, oncology, and organ health. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. Forward-looking Statements Except for historical information, certain statements in this press …

Natera to Present at the Morgan Stanley 18th Annual Global Healthcare Conference | PR Newswire | 9/10/2020

… a focus on women’s health, oncology, and organ health. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California . It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com . Follow Natera on LinkedIn . Contacts Investor Relations …

NeoGenomics To Virtually Participate In Fireside Chat At The 18th Annual Morgan Stanley Global Healthcare Conference | 9/10/2020

NeoGenomics To Virtually Participate In Fireside Chat At The 18th Annual Morgan Stanley Global Healthcare Conference Investor Relations Download as PDF September 10, 2020 FT MYERS, FL / ACCESSWIRE / September 10, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services , today announced that Doug VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer and Doug Brown, Chief Strategy and Corporate Development Officer, will be …

Millennium Health and the Ohio Department of Public Safety Collaborate to Help Save Lives Amid COVID-19 and the Substance Use Crisis | PR Newswire | 9/9/2020

… as well as many other specialties to obtain objective information about patients’ recent use of prescription medications and/or illicit drugs and helps monitor the effectiveness of treatment plans. Our evidence-based, guideline-driven genetic testing services , including pharmacogenetic testing , help clinicians make more informed medication choices for their patients. Visit millenniumhealth.com for more information. SOURCE Millennium Health, LLC Related Links https://www.millenniumhealth.com …

Genetic Testing Services Market Business Growth, Development Factors, Applications, and Future Prospects | 9/8/2020

Facebook Transparency Market Research (TMR) has published a new report titled, ‘Genetic Testing Services Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.According to the report, the global Genetic Testing Services market was valued at US$ 41.2 Bn in 2018 and is projected to expand at a CAGR of 7.3% from 2019 to 2027. Overview Genetic Testing is a medical test also known as DNA testing …

Fulgent Genetics (NASDAQ:FLGT) Cut to “Hold” at Zacks Investment Research | 9/6/2020

Zacks Investment Research cut shares of Fulgent Genetics (NASDAQ:FLGT) from a buy rating to a hold rating in a report published on Thursday morning, Zacks.com reports. According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process …

Fulgent Genetics (NASDAQ:FLGT) Downgraded to Hold at Zacks Investment Research | Daily Political | 9/4/2020

Zacks Investment Research downgraded shares of Fulgent Genetics (NASDAQ:FLGT) from a buy rating to a hold rating in a research note published on Thursday, Zacks.com reports. According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process …

SMART Study Data for Aneuploidy and 22q Unblinded | PR Newswire | 9/3/2020

… a focus on women’s health, oncology, and organ health. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California . It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com . Follow Natera on LinkedIn . Forward-Looking Statements …

California Senate Passes Bill Establishing the Genetic Information Privacy Act | 9/3/2020

… Gavin Newsom’s signature. The Genetic Information Privacy Act will introduce new requirements for companies offering direct-to-consumer genetic tests to protect consumer privacy and safeguard personal and genetic data. Currently, direct-to-consumer genetic testing services are largely unregulated. There is concern that the practices of companies that offer these services could potentially expose sensitive genetic information and that outside parties could exploit the use of genetic data for …

Natera Receives Final Medicare Coverage for its Signatera™ MRD Test in Stage II-III Colorectal Cancer | PR Newswire | 9/3/2020

… a focus on women’s health, oncology, and organ health. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California . It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com . Follow Natera on LinkedIn . About Signatera Signatera …

Stock Alert: Fulgent Genetics Up 20% On COVID-19 Testing Deal For NY Schools | 9/3/2020

Shares of Fulgent Genetics Inc. ( FLGT ) are currently gaining nearly 20% on Thursday morning. The other day, the genetic testing services company said it would supply COVID-19 testing to hundreds of thousands of students in collaboration with New York City Health and Hospitals at nearly 1,600 locations. FLGT is currently trading at $34.52, up $6.14 or 21.28%, on the Nasdaq. The California-based company will supply its RT-PCR …

Fulgent Genetics (NASDAQ:FLGT) Upgraded by Zacks Investment Research to Buy | Daily Political | 9/3/2020

Zacks Investment Research upgraded shares of Fulgent Genetics (NASDAQ:FLGT) from a hold rating to a buy rating in a report released on Wednesday, Zacks.com reports. They currently have $32.00 price target on the stock. According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software …

Women’s Excellence Launches Ovarian Cancer Awareness Campaign for the Month of September | PRWeb | 9/2/2020

… genetic testing) can be an important tool for many women to determine if a patient has a genetic predisposition that is linked to cancers like ovarian cancer and breast cancer. “We’re thrilled to have genetic testing services in our offices for women. We are able to use these results to develop an appropriate care plan to monitor and screen for these cancers more frequently,” says Dr. Zaidan. Throughout the month …

Zacks Investment Research Downgrades Fulgent Genetics (NASDAQ:FLGT) to Hold | 9/1/2020

Zacks Investment Research downgraded shares of Fulgent Genetics (NASDAQ:FLGT) from a buy rating to a hold rating in a report issued on Friday, Zacks.com reports. According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which …

Study Shows Clinical Utility of the Prospera™ Test in Nephrology Practice | PR Newswire | 9/1/2020

… a focus on reproductive health, oncology, and organ transplantation. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com . Follow Natera on LinkedIn . Forward-Looking Statements …

Genetic Testing Services Market: Surge in Adoption of Genetic Testing Services to Boost the Market | BioSpace | 9/1/2020

Transparency Market Research (TMR) has published a new report titled, ‘Genetic Testing Services Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.According to the report, the global Genetic Testing Services market was valued at US$ 41.2 Bn in 2018 and is projected to expand at a CAGR of 7.3% from 2019 to 2027. Overview Genetic Testing is a medical test also known as DNA testing which …

Fulgent Genetics (NASDAQ:FLGT) Upgraded to “Buy” at Zacks Investment Research | 8/31/2020

… buy rating in a research note published on Thursday morning, Zacks.com reports. The firm currently has $50.00 target price on the stock. According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals …

Fulgent Genetics (NASDAQ:FLGT) Stock Rating Lowered by Zacks Investment Research | 8/30/2020

… Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, Zacks.com reports. According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals …

Fulgent Genetics (NASDAQ:FLGT) Upgraded at Zacks Investment Research | 8/30/2020

… buy rating in a research report report published on Thursday, Zacks.com reports. The firm currently has $50.00 target price on the stock. According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals …

Zacks Investment Research Upgrades Fulgent Genetics (NASDAQ:FLGT) to “Buy” | 8/29/2020

… target price on the stock. Zacks Investment Research ‘s target price indicates a potential upside of 65.29% from the company’s previous close. According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals …

Fulgent Genetics (NASDAQ:FLGT) Upgraded to “Buy” at Zacks Investment Research | Daily Political | 8/28/2020

… rating in a research note published on Thursday morning, Zacks.com reports. Zacks Investment Research currently has $50.00 price target on the stock. According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals …

Global Genetic Testing Industry Outlook to 2023 with Market Shares by Key Players | PR Newswire | 8/28/2020

… Genome Sequencing growing $1500 to sequence newborns in China Scientists discover new nanoparticle, dubbed exomeres, released by tumours New DNA tests look for 190 diseases in newborn’s genetic code Cordlife, PlumCare Partner to Offer Genetic Testing Services in Asia New genetic risk score could help guide screening decisions for prostate cancer Tele-genetics pilot makes genetic counselling accessible Digital Genetic Assistant OptraGURU Launches Today From Optra Health PacBridge Capital Partners …

Natera Announces Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer | PR Newswire | 8/27/2020

… a focus on women’s health, oncology, and organ health. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers proprietary genetic testing services to oncologists, obstetricians, and transplant physicians, as well as to researchers and biopharmaceutical companies. For more information, visit natera.com . Follow Natera on LinkedIn . Forward-Looking Statements All statements other than statements of historical …

Food and Drug Administration

Panorama Publication Demonstrates Utility of Measuring Individual Fetal Fractions in Twin Pregnancies | PR Newswire | 11/27/2019

… laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed … in San Carlos, Calif. It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its …

Panorama NIPT Achieves 2 Million Test Milestone | PR Newswire | 8/22/2019

… laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed … in San Carlos, Calif. It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based …

Precision Medicine

Golden Meditech Announces FY2019/2020 Interim Results | PR Newswire | 11/27/2019

… 163,913 (4.1) Healthcare services segment revenue 75,375 83,599 (9.8) Hospital business income 72,201 75,612 (4.5) Cells and tissues storage and genetic testing services income 154 5,324 (97.1) Medical insurance administration services income 3,020 2,663 13.4 … application to other diseases such as haematologic and demyelinating diseases. Precision Medicine Business Golden Meditech Javadi Precision Medicine Limited (“GM Javadi”), a 40.0% joint venture of the Group, owns a renowned day clinic in the …

Sunquest Information Systems Partners with NGS Clinical Interpretation Leader, N-of-One | PR Newswire | 11/17/2017

… Worldwide Offices Sunquest Information Systems Partners with NGS Clinical Interpretation Leader, N-of-One CellNetix, an anatomic pathology laboratory delivering genetic testing services, is working with Sunquest and N-of-One to expand and scale … genetic analysis and reporting software suite for molecular diagnostics and precision medicine, will allow pathologists in hospitals and reference laboratories to streamline delivery of time-critical, case-specific genetic reports with high-quality clinical interpretation …

Pharmacogenomic Testing

Mayo Clinic Spinoff OneOme to Bring Genetic Testing Services to the Netherlands - Twin Cities Business | 11/21/2019

… Mayo Clinic-spinoff OneOme is expanding overseas. The Minneapolis-based startup—which specializes in “pharmacogenomics,” the study of how genes affect individual responses to medications—is partnering with Alliance Healthcare Netherlands to bring pharmacogenomic testing to pharmacies throughout Holland. (Alliance Healthcare Netherlands is a subsidiary of Walgreens Boots Alliance Inc., a holding company that owns Walgreens and other pharmacy chains.) In the initial pilot, pharmacists at 18 Boots and Alphega …

Global Genetic Testing Market to 2024: CGES Testing - A Brave New World | PR Newswire | 11/14/2019

… forecasts the market size out to 2024. The report includes detailed breakouts for 14 countries and 5 regions. Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that … diseases in newborn’s genetic code Cordlife, PlumCare Partner to Offer Genetic Testing Services in Asia New genetic risk score could help guide screening decisions for prostate cancer Tele-genetics pilot makes genetic counselling accessible Digital …

Medicare

Global Genetic Testing Market to 2024: CGES Testing - A Brave New World | PR Newswire | 11/14/2019

… The Genomics Revolution 1.3 Market Definition 1.3.1 Revenue Market Size 1.4 U.S. Medical Market and laboratory Testing - Perspective 1.4.1 U.S. Medicare Expenditures for Laboratory Testing 2. Market Overview 2.1 Market Participants Play Different Roles 2.1.1 … diseases in newborn’s genetic code Cordlife, PlumCare Partner to Offer Genetic Testing Services in Asia New genetic risk score could help guide screening decisions for prostate cancer Tele-genetics pilot makes genetic counselling accessible Digital …

Natera Reports Third Quarter 2019 Financial Results | PR Newswire | 11/6/2019

… tests accessioned in the third quarter of 2018, an increase of approximately 25%. Received positive draft local coverage decision from Medicare for reimbursement of Signatera™ in colorectal cancer. Completed key technical and commercialization milestones with … Improvement Amendments (CLIA) in San Carlos, California . It offers proprietary genetic testing services to inform physicians who care for pregnant women, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its …

Genomics

Global Genetic Testing Market to 2024: CGES Testing - A Brave New World | PR Newswire | 11/14/2019

… next five years. Key Topics Covered: 1. Introduction and Market Definition 1.1 Genetic Testing Definition in This Report 1.2 The Genomics Revolution 1.3 Market Definition 1.3.1 Revenue Market Size 1.4 U.S. Medical Market and laboratory … diseases in newborn’s genetic code Cordlife, PlumCare Partner to Offer Genetic Testing Services in Asia New genetic risk score could help guide screening decisions for prostate cancer Tele-genetics pilot makes genetic counselling accessible Digital …

China Genetic Testing Market by Test Type, Disease, Technology, Service Provider, Testing Sample 2019-2024 | The Wapakoneta Daily News | 11/11/2019

genomics company in 1999. The demand for genetic testing services in the country is being driven by factors like aging population, expanding middle class and investments in the healthcare sector. The industry has also attracted international investors owing to rising demand for noninvasive prenatal testing and growing research in the fields of reproductive and oncology health. Get a PDF Sample for more detailed market insights: https://www.imarcgroup.com/china-genetic-testing …

Diagnostic Tests

Global Genetic Testing Market to 2024: CGES Testing - A Brave New World | PR Newswire | 11/14/2019

… Medicine Rapid genome sequencing could revolutionize health care Scientists discover new nanoparticle, dubbed exomeres, released by tumours New DNA tests look for 190 diseases in newborn’s genetic code Cordlife, PlumCare Partner to Offer Genetic Testing Services in Asia New genetic risk score could help guide screening decisions for prostate cancer Tele-genetics pilot makes genetic counselling accessible Digital Genetic Assistant OptraGURU Launches Today from Optra Health PacBridge Capital Partners Invests …

Diagnostic Deals: A roundup of the key mergers, acquisitions, alliances, licenses and other strategic transactions from the past month | 10/31/2019

… rapid, quantitative point-of-care tests Dynamic: ProciseDx to get exclusive worldwide rights to use Lumiphore’s reporter technology in its diagnostic tests New Horizon Health Prenetics Objective: Commercialize New Horizon’s ColoClear colorectal cancer test in … 2020 BC Platforms Blueprint Genetics Objective: Develop data-driven clinical genetic testing services for patients with rare diseases Dynamic: Combine Blueprint Genetics’ clinical genetic testing services with BC Platforms’ data management technology to help hospital …

Regenerative Medicine

CBR to Acquire Natera’s Evercord™ Cord Blood Business | Markets Insider | Business Insider | 9/13/2019

… safeguarding these newborn stem cells and allowing the Evercord families to take advantage of future advances in cellular therapies and regenerative medicine.” CBR will work closely with Natera to ensure a smooth transition for customers … in San Carlos, Calif. It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, researchers in cancer including biopharmaceutical companies, and genetic laboratories through its cloud-based software …

CBR® Acquires Evercord™ Newborn Stem Cell Business from Natera | Markets Insider | Business Insider | 9/13/2019

… safeguarding these newborn stem cells, and allowing the Evercord families to take advantage of future advances in cellular therapies and regenerative medicine.” “This divestiture will allow Natera to focus squarely on its core genetic testing … in San Carlos, Calif. It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, researchers in cancer including biopharmaceutical companies, and genetic laboratories through its cloud-based software …

Behavioral Health

Q&A: NeuroFlow and Genomind Team Up to Advance Mental Health Care | 9/4/2019

behavioral health specialists and psychologists to remotely monitor a patient’s mental wellness. The new partnership will give providers access to NeuroFlow ’s mental health remote monitoring apps alongside Genomind ’s Professional PGx Express genetic testing services, which combined, may enable physicians to better understand their patients’ genetics and how genetics may affect mental health, and to remotely track progress along the entire patient journey. NextHealth PHL spoke with NeuroFlow chief …

Genomind Expands Mental Health Genetic Testing Services with New Genomind Professional PGx Express | Business & Finance | heraldchronicle.com | Business Wire | 8/5/2019

… certain genetic variants related to drug metabolism; the ‘metatype’ can have a critical impact on the effects of drugs on that individual patient; Access to NeuroFlow , a progressive collaborative care digital platform of behavioral health smart phone apps to help the care team and patients better track compliance with treatment plans and enable remote monitoring and measurement-based care. Genomind’s ‘express’ reporting and consults will enable a broader range of …

Laboratory Information Management

Sunquest Information Systems Partners with NGS Clinical Interpretation Leader, N-of-One | PR Newswire | 11/17/2017

… Worldwide Offices Sunquest Information Systems Partners with NGS Clinical Interpretation Leader, N-of-One CellNetix, an anatomic pathology laboratory delivering genetic testing services, is working with Sunquest and N-of-One to expand and scale … The integration of N-of-One and Sunquest Mitogen™, a laboratory information management system (LIMS) and genetic analysis and reporting software suite for molecular diagnostics and precision medicine, will allow pathologists in hospitals and reference …

Sunquest Information Systems Partners with NGS Clinical Interpretation Leader, N-of-One | PR Newswire | 11/17/2017

… the leader in clinical interpretation for molecular diagnostics in oncology. The integration of N-of-One and Sunquest Mitogen™, a laboratory information management system (LIMS) and genetic analysis and reporting software suite for molecular diagnostics … is ideally suited to help laboratories start and scale their genetic testing services from the wet bench to the dry lab for hereditary conditions and somatic cancer.” “The integration of N-of-One clinical interpretation …

MEDITECH

Golden Meditech Announces FY2019/2020 Annual Results | PR Newswire | 6/30/2020

… 315,668 (2.7) Healthcare services segment revenue 151,600 167,752 (9.6) Hospital services income 145,043 147,014 (1.3) Cells and tissues storage and genetic testing services income 1,521 13,692 (88.9) Medical insurance administration services income 5,036 7,046 (28.5 … 3) and ( 5 ). HONG KONG , June 30, 2020 /PRNewswire/ – Golden Meditech Holdings Limited (SEHK stock code: 00801) (“Golden Meditech” or the “Company”, together with its subsidiaries, the “Group”), a leading integrated healthcare enterprise in China …

Golden Meditech Announces FY2019/2020 Interim Results | PR Newswire | 11/27/2019

… 163,913 (4.1) Healthcare services segment revenue 75,375 83,599 (9.8) Hospital business income 72,201 75,612 (4.5) Cells and tissues storage and genetic testing services income 154 5,324 (97.1) Medical insurance administration services income 3,020 2,663 13.4 … signed with Sanpower. (4) Excluding (1), (2) and (3). Golden Meditech Holdings Limited (SEHK stock code: 00801) (“Golden Meditech” or the “Company”, together with its subsidiaries, the “Group”), a leading integrated healthcare enterprise in China …

Genomic Health

Global Genetic Testing Market to 2024: CGES Testing - A Brave New World | PR Newswire | 11/14/2019

… exomeres, released by tumours New DNA tests look for 190 diseases in newborn’s genetic code Cordlife, PlumCare Partner to Offer Genetic Testing Services in Asia New genetic risk score could help guide screening decisions for … Ltd Genedrive GeneFirst Ltd Genetron Health ( Beijing ) Co., Ltd Genewiz Genomic Health Genomics England Genomics Personalized Health (GPH) GenomOncology Genzyme Corporation Grail, Inc Grifols Guardant Health Guardiome HeiScreen Helix Helomics Hologic Horizon Discovery HTG Molecular …

Genetic Testing Services Market to 2027 – Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Illumina, Quest Diagnostics Incorporated, Genomic Health, Ambry Genetics | 11/12/2019

Press Releases Genetic Testing Services Market to 2027 – Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Illumina, Quest Diagnostics Incorporated, Genomic Health, Ambry Genetics Worldwide Genetic Testing Services Market Analysis to 2027 is a specialized and in-depth study of the global industry with a focus on the global market trend. The report aims to provide an overview of global Genetic Testing Services market with detailed market segmentation …

Qiagen

Global Genetic Testing Market to 2024: CGES Testing - A Brave New World | PR Newswire | 11/14/2019

… Qiagen, NeuMoDx Ink Partnership, Merger Agreement Prenetics Acquires DNAFit for $10M Myriad Genetics to Acquire Counsyl for $375M Roche inks $2.4B deal to buy out Foundation Medicine Rapid genome sequencing could revolutionize health care Scientists discover new nanoparticle, dubbed exomeres, released by tumours New DNA tests look for 190 diseases in newborn’s genetic code Cordlife, PlumCare Partner to Offer Genetic Testing Services in Asia New genetic risk score could help …

Natera stock price target raised to $32 from $27 at J.P. Morgan | MarketWatch | 11/4/2019

… Qiagen, Gen-Probe Inc., Digene Corporation, Abbott Molecular, IVDiagnostics Sep. 23, 2019 at 10:17 a.m. ET on Heraldkeepers Non-invasive Prenatal Testing (NIPT) Market Is Estimated To Expand At a Healthy CAGR in the Upcoming Forecast 2025 Sep. 23, 2019 at 6:14 a.m. ET on AmericaNewsHour Natera Inc. Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier …

Thermo Fisher

Global Genetic Testing Market to 2024: CGES Testing - A Brave New World | PR Newswire | 11/14/2019

… Risk Arivale Shuts Down Personalized Wellness Business ArcherDX Acquires Baby Genes MDxHealth, LifeLabs Ink Distribution Agreement for Prostate Cancer Assay Thermo Fisher Purchases 9 Percent Stake in Yourgene Health Invitae Partners to Expand Free Epilepsy … diseases in newborn’s genetic code Cordlife, PlumCare Partner to Offer Genetic Testing Services in Asia New genetic risk score could help guide screening decisions for prostate cancer Tele-genetics pilot makes genetic counselling accessible Digital …

Genetic Testing Markets, World Outlook to 2024 - Fertility Practice Growth Drives the Market, Pharmacogenomics Drives Further Growth | Globe Newswire | 11/1/2019

… Risk Arivale Shuts Down Personalized Wellness Business ArcherDX Acquires Baby Genes MDxHealth, LifeLabs Ink Distribution Agreement for Prostate Cancer Assay Thermo Fisher Purchases 9 Percent Stake in Yourgene Health Invitae Partners to Expand Free Epilepsy … diseases in newborn’s genetic code Cordlife, PlumCare Partner to Offer Genetic Testing Services in Asia New genetic risk score could help guide screening decisions for prostate cancer Tele-genetics pilot makes genetic counselling accessible Digital …

Thermo Fisher Scientific

Global Genetic Testing Market to 2024: CGES Testing - A Brave New World | PR Newswire | 11/14/2019

… exomeres, released by tumours New DNA tests look for 190 diseases in newborn’s genetic code Cordlife, PlumCare Partner to Offer Genetic Testing Services in Asia New genetic risk score could help guide screening decisions for … Genomics Sure Genomics, Inc Sysmex Sysmex Inostics Tempus Labs, Inc Thermo Fisher Scientific Inc Veritas Genetics Volition 6. Global Market Size 6.1 Global Market by Country 6.2 Global Market by Application 7. Market Sizes by …

Diagnostic Deals: A roundup of the key mergers, acquisitions, alliances, licenses and other strategic transactions from the past month | 10/31/2019

… and particle validation standards businesses to secure regulatory antitrust approval for its pending $21.4 billion acquisition of GE Biopharma business Thermo Fisher Scientific Price: €90 million ($98.4 million) Status: Closed Thermo Fisher acquires active pharmaceutical … 2020 BC Platforms Blueprint Genetics Objective: Develop data-driven clinical genetic testing services for patients with rare diseases Dynamic: Combine Blueprint Genetics’ clinical genetic testing services with BC Platforms’ data management technology to help hospital …

Novartis

Epigenetics Market Overview & Potential Growth Opportunities Report To 2025 | Key Players: Illumina, Abcam, Novartis, Merck & Oncolys Biopharma | Million Insights | Markets Insider | Business Insider | 10/29/2019

… patients suffering from chronic diseases and successful execution of disease management are other major factors driving the growth of the genetic testing services domain. High-end demand for latest technologies in healthcare sector and collective … Qiagen, Inc., CellCentric Ltd., Chroma Therapeutics Ltd., Eisai Co., Ltd., Novartis International AG, Oncolys Biopharma Inc., Syndax Pharmaceuticals, Inc., Valirx Plc, and Sigma-Aldrich Corp. Browse 153 page research report with TOC on “Global Epigenetics …

Epigenetics Market Overview & Potential Growth Opportunities Report To 2025 | Key Players: Illumina, Abcam, Novartis, Merck & Oncolys Biopharma | Million Insights | Markets Insider | Business Insider | 10/29/2019

… patients suffering from chronic diseases and successful execution of disease management are other major factors driving the growth of the genetic testing services domain. High-end demand for latest technologies in healthcare sector and collective … Qiagen, Inc., CellCentric Ltd., Chroma Therapeutics Ltd., Eisai Co., Ltd., Novartis International AG, Oncolys Biopharma Inc., Syndax Pharmaceuticals, Inc., Valirx Plc, and Sigma-Aldrich Corp. Browse 153 page research report with TOC on “Global Epigenetics …

Merck

Epigenetics Market Overview & Potential Growth Opportunities Report To 2025 | Key Players: Illumina, Abcam, Novartis, Merck & Oncolys Biopharma | Million Insights | Markets Insider | Business Insider | 10/29/2019

… patients suffering from chronic diseases and successful execution of disease management are other major factors driving the growth of the genetic testing services domain. High-end demand for latest technologies in healthcare sector and collective … Illumina, Inc., Abcam, Inc., Diagenode S.A., Thermo Fisher Scientific Group, Merck & Co., Inc., Zymo Research Corp., Qiagen, Inc., CellCentric Ltd., Chroma Therapeutics Ltd., Eisai Co., Ltd., Novartis International AG, Oncolys Biopharma Inc., Syndax Pharmaceuticals, Inc …

Epigenetics Market Overview & Potential Growth Opportunities Report To 2025 | Key Players: Illumina, Abcam, Novartis, Merck & Oncolys Biopharma | Million Insights | Markets Insider | Business Insider | 10/29/2019

… patients suffering from chronic diseases and successful execution of disease management are other major factors driving the growth of the genetic testing services domain. High-end demand for latest technologies in healthcare sector and collective … Illumina, Inc., Abcam, Inc., Diagenode S.A., Thermo Fisher Scientific Group, Merck & Co., Inc., Zymo Research Corp., Qiagen, Inc., CellCentric Ltd., Chroma Therapeutics Ltd., Eisai Co., Ltd., Novartis International AG, Oncolys Biopharma Inc., Syndax Pharmaceuticals, Inc …

Illumina

Epigenetics Market Overview & Potential Growth Opportunities Report To 2025 | Key Players: Illumina, Abcam, Novartis, Merck & Oncolys Biopharma | Million Insights | Markets Insider | Business Insider | 10/29/2019

… patients suffering from chronic diseases and successful execution of disease management are other major factors driving the growth of the genetic testing services domain. High-end demand for latest technologies in healthcare sector and collective … epigenetics testing in preventive healthcare management. The key players are Illumina, Inc., Abcam, Inc., Diagenode S.A., Thermo Fisher Scientific Group, Merck & Co., Inc., Zymo Research Corp., Qiagen, Inc., CellCentric Ltd., Chroma Therapeutics Ltd., Eisai Co …

Epigenetics Market Overview & Potential Growth Opportunities Report To 2025 | Key Players: Illumina, Abcam, Novartis, Merck & Oncolys Biopharma | Million Insights | Markets Insider | Business Insider | 10/29/2019

… patients suffering from chronic diseases and successful execution of disease management are other major factors driving the growth of the genetic testing services domain. High-end demand for latest technologies in healthcare sector and collective … epigenetics testing in preventive healthcare management. The key players are Illumina, Inc., Abcam, Inc., Diagenode S.A., Thermo Fisher Scientific Group, Merck & Co., Inc., Zymo Research Corp., Qiagen, Inc., CellCentric Ltd., Chroma Therapeutics Ltd., Eisai Co …

Sunquest

Sunquest Information Systems Partners with NGS Clinical Interpretation Leader, N-of-One | PR Newswire | 11/17/2017

Worldwide Offices Sunquest Information Systems Partners with NGS Clinical Interpretation Leader, N-of-One CellNetix, an anatomic pathology laboratory delivering genetic testing services, is working with Sunquest and N-of-One to expand and scale its delivery of excellence in molecular pathology. News provided by 14:46 ET Share this article TUCSON, Ariz. , Nov. 17, 2017 /PRNewswire/ – Sunquest Information Systems, Inc., the leader in diagnostic informatics for laboratories, announced today its …

Sunquest Information Systems Partners with NGS Clinical Interpretation Leader, N-of-One | PR Newswire | 11/17/2017

TUCSON, Ariz. , Nov. 17, 2017 /PRNewswire/ – Sunquest Information Systems, Inc., the leader in diagnostic informatics for laboratories, announced today its partnership with N-of-One, the leader in clinical interpretation for molecular diagnostics in oncology … is ideally suited to help laboratories start and scale their genetic testing services from the wet bench to the dry lab for hereditary conditions and somatic cancer.” “The integration of N-of-One clinical interpretation …

CombiMatrix

Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health Genetic Information Services | PR Newswire | 11/15/2017

Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health Genetic Information Services – Complements recent acquisition of Good Start Genetics to establish comprehensive service for IVF clinics, ob/gyns —- Entry into family … prenatal and perinatal genetics, currently the second-largest category of genetic testing services. Our integrated offering will build on the expertise and technologies developed by CombiMatrix to offer customers the most comprehensive offering from a …

Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health | PR Newswire | 11/15/2017

CombiMatrix, which specializes in providing genetic information for prenatal diagnosis, miscarriage analysis and diagnosis of pediatric developmental disorders, establishing Invitae as a new leader in family and reproductive genetic health services. “With the addition of CombiMatrix to Invitae, we have completed our entry into prenatal and perinatal genetics, currently the second-largest category of genetic testing services. Our integrated offering will build on the expertise and technologies developed by CombiMatrix

Morgan Stanley

Natera Announces Pricing of Follow-On Offering | PR Newswire | 10/17/2019

… shares of its common stock from Natera at the public offering price less the underwriting discounts and commissions. J.P. Morgan, Morgan Stanley, Cowen and Piper Jaffray are acting as joint book-running managers for the … Improvement Amendments (CLIA) in San Carlos, Calif. It offers proprietary genetic testing services to inform physicians who care for pregnant women, oncologists, and cancer researchers, including bio pharmaceutical companies, and genetic laboratories through its cloud …

Natera Launches Proposed Follow-On Offering | PR Newswire | 10/16/2019

… or when the offering may be completed, or as to the actual size or terms of the offering. J.P. Morgan, Morgan Stanley, Cowen, and Piper Jaffray are acting as joint book-running managers for the … Improvement Amendments (CLIA) in San Carlos, Calif. It offers proprietary genetic testing services to inform physicians who care for pregnant women, oncologists, and cancer researchers, including bio pharmaceutical companies, and genetic laboratories through its cloud …

Piper Jaffray

Natera Announces Pricing of Follow-On Offering | PR Newswire | 10/17/2019

… stock from Natera at the public offering price less the underwriting discounts and commissions. J.P. Morgan, Morgan Stanley, Cowen and Piper Jaffray are acting as joint book-running managers for the offering. Baird and Craig … Improvement Amendments (CLIA) in San Carlos, Calif. It offers proprietary genetic testing services to inform physicians who care for pregnant women, oncologists, and cancer researchers, including bio pharmaceutical companies, and genetic laboratories through its cloud …

Natera Launches Proposed Follow-On Offering | PR Newswire | 10/16/2019

… may be completed, or as to the actual size or terms of the offering. J.P. Morgan, Morgan Stanley, Cowen, and Piper Jaffray are acting as joint book-running managers for the offering. Baird and Craig … Improvement Amendments (CLIA) in San Carlos, Calif. It offers proprietary genetic testing services to inform physicians who care for pregnant women, oncologists, and cancer researchers, including bio pharmaceutical companies, and genetic laboratories through its cloud …

Mike Brophy

Natera Announces Second Quarter 2020 Earnings Conference Call | PR Newswire | 7/29/2020

genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com . Follow Natera on LinkedIn . Contacts Investor Relations: Mike Brophy , CFO, Natera, Inc., 650-249-9090 Media: Paul Greenland , VP of Corporate Marketing, Natera, Inc., [email protected] SOURCE Natera, Inc. Related Links https://www.natera.com …

Natera Files Patent Suit Against Progenity, Inc. | PR Newswire | 6/17/2020

… certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies … are available at www.natera.com/investors and www.sec.gov . Contacts Investor Relations: Mike Brophy , CFO, Natera, Inc., 510-330-2971 Media: Paul Greenland , VP of Corporate Marketing, Natera, Inc., [email protected] SOURCE Natera, Inc. Related Links http://www.natera.com …

Alexey Aleshin

Natera Announces Clinical Data at ESMO GI Supporting Personalized ctDNA Testing for Oligometastatic Colorectal Cancer (CRC) Patients | PR Newswire | 7/7/2020

… inform treatment decisions after oligometastatic resection in the 20 percent to 30 percent of patients with metastatic CRC,” 1-3 said Alexey Aleshin , M.D., M.B.A., Natera’s Senior Medical Director for Oncology. “This clinical data suggest ctDNA … Improvement Amendments (CLIA) in San Carlos, Calif. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For …

Natera Announces First Patient Enrollments in Both CIRCULATE-Japan and BESPOKE CRC Trials Using Signatera™ MRD Testing | PR Newswire | 6/18/2020

… recurrence monitoring tools in colorectal cancer and a growing consensus around Signatera’s personalized technology as the right diagnostic approach,” said Alexey Aleshin , M.D., M.B.A., Natera’s Senior Medical Director of Oncology. In addition to the multiple … Improvement Amendments (CLIA) in San Carlos, Calif. It offers proprietary genetic testing services to inform physicians who care for pregnant women, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based …

Steve Chapman

Natera Expands Lab Footprint With State-Of-The-Art Facility in Austin, Texas | PR Newswire | 6/22/2020

… 25 billion dollar opportunity. This expansion will enable us to penetrate these markets in a streamlined, cost-effective manner,” said Steve Chapman , Natera’s Chief Executive Officer. Natera processes thousands of medical tests each business day … in San Carlos, California , and Austin, Texas . It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For …

Natera Announces Preliminary First Quarter 2020 Financial Results | PR Newswire | 4/13/2020

… we are encouraged to see the recent expansion in average risk NIPT covered lives that occurred in late March,” said Steve Chapman , Natera’s CEO. Fiscal Year 2020 Outlook: As a result of the highly dynamic … Improvement Amendments (CLIA) in San Carlos, Calif. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For …

Feng Wen

Golden Meditech Announces FY2018/2019 Annual Results | Business & Finance | manchestertimes.com | PR Newswire | 6/28/2019

… each business unit under the core healthcare services segment has achieved satisfactory progress, among which, cells-and-tissues storage and genetic testing services businesses and hospital business have achieved significant growth, becoming the key drivers … increased share of losses of associates and joint ventures. Mr. Feng Wen, Chairman of the Group, said, “Comprehensive and in-depth penetration of the ‘Healthy China’ strategy has uplifted the healthcare industry’s status in China …

Golden Meditech Announces FY2018/2019 Annual Results | PR Newswire | 6/28/2019

… 250,719 25.9 Healthcare services segment revenue 167,752 113,548 47.7 Hospital services income 147,014 107,118 37.2 Cells and tissues storage and genetic testing services income 13,692 944 1,350.4 Medical insurance administration services income 7,046 5,486 28.4 … increased share of losses of associates and joint ventures. Mr. Feng Wen , Chairman of the Group, said, “Comprehensive and in-depth penetration of the ‘Healthy China’ strategy has uplifted the healthcare industry’s status in China …

Claus Lindbjerg Andersen

New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier | Markets Insider | Business Insider | 5/9/2019

… multiplex PCR-based next-generation sequencing is a highly sensitive approach for detecting molecular residual disease in the blood,” said Claus Lindbjerg Andersen , M.Sc., Ph.D., study lead investigator, Aarhus University. “The results show the potential … in San Carlos, Calif. It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, researchers in cancer including biopharmaceutical companies, and genetic laboratories through its cloud-based software …

New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier | PR Newswire | 5/9/2019

… were published in the May issue of JAMA Oncology . Colorectal Cancer Study Alexey Aleshin, M.D., MBA, Natera’s oncology medical director Claus Lindbjerg Andersen, M.Sc., Ph.D., study lead investigator, Aarhus University The prospective, multicenter study enrolled … in San Carlos, Calif. It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, researchers in cancer including biopharmaceutical companies, and genetic laboratories through its cloud-based software …

Sean George

Invitae Reports 47% Growth in Quarterly Revenue and Volume Year-Over-Year | PR Newswire | 5/7/2019

… 2019 guidance and in 2020 to serve more than one million patients with more than $500 million in revenue,” said Sean George , co-founder and chief executive officer of Invitae. “Invitae is rapidly becoming the … maternal cell-free DNA, rounding out Invitae’s comprehensive women’s health genetic testing services Named as one of seven labs in UnitedHealthcare’s (UHC) Preferred Lab Network designed to make it easier for providers to choose from …

Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health Genetic Information Services | PR Newswire | 11/15/2017

… genetic testing services. Our integrated offering will build on the expertise and technologies developed by CombiMatrix to offer customers the most comprehensive offering from a single provider in the category,” said Sean George , chief executive officer of Invitae. “Invitae’s platform now delivers comprehensive genetic information services that support the use of genetics in mainstream medical care throughout all stages of life.” CombiMatrix leverages cytogenomic and cytogenetic technologies such as single …

Brian Chesky

IPOs in 2018: Here are six tech companies that could go public - MarketWatch | 12/27/2017

… so. “We will go public when it’s right for us,” Lyft spokeswoman Alexandra LaManna said. For its part, Airbnb CEO Brian Chesky said in October that the company is “halfway” through its two-year project … 23andMe Inc. is an interesting animal. The company sells its genetic testing services to consumers, then turns around and sells that data in aggregate to research institutes and nonprofits. It also has hopes for an …

IPOs in 2018: Here are six tech companies that could go public - MarketWatch | 12/26/2017

… so. “We will go public when it’s right for us,” Lyft spokeswoman Alexandra LaManna said. For its part, Airbnb CEO Brian Chesky said in October that the company is “halfway” through its two-year project … 23andMe Inc. is an interesting animal. The company sells its genetic testing services to consumers, then turns around and sells that data in aggregate to research institutes and nonprofits. It also has hopes for an …

Anna Berry

Sunquest Information Systems Partners with NGS Clinical Interpretation Leader, N-of-One | PR Newswire | 11/17/2017

… Worldwide Offices Sunquest Information Systems Partners with NGS Clinical Interpretation Leader, N-of-One CellNetix, an anatomic pathology laboratory delivering genetic testing services, is working with Sunquest and N-of-One to expand and scale … and in turn bring better care to more patients,” said Anna Berry , director of molecular pathology at CellNetix Pathology and Laboratories. CellNetix is an innovative, state-of-the-art anatomic pathology laboratory that provides cancer …

Sunquest Information Systems Partners with NGS Clinical Interpretation Leader, N-of-One | PR Newswire | 11/17/2017

… treating patients with cancer. The latest release of Sunquest Mitogen is ideally suited to help laboratories start and scale their genetic testing services from the wet bench to the dry lab for hereditary conditions and … and in turn bring better care to more patients,” said Anna Berry , director of molecular pathology at CellNetix Pathology and Laboratories. CellNetix is an innovative, state-of-the-art anatomic pathology laboratory that provides cancer …

Robert Nussbaum

Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health Genetic Information Services | PR Newswire | 11/15/2017

… of CombiMatrix to Invitae, we have completed our entry into prenatal and perinatal genetics, currently the second-largest category of genetic testing services. Our integrated offering will build on the expertise and technologies developed by … for women going through IVF or facing recurrent miscarriages,” said Robert Nussbaum , MD, chief medical officer of Invitae. “Our integrated platform and world-class expertise can provide genetic information that helps women and their clinicians …

Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health | PR Newswire | 11/15/2017

… of CombiMatrix to Invitae, we have completed our entry into prenatal and perinatal genetics, currently the second-largest category of genetic testing services. Our integrated offering will build on the expertise and technologies developed by … for women going through IVF or facing recurrent miscarriages,” said Robert Nussbaum , MD, chief medical officer of Invitae. “Our integrated platform and world-class expertise can provide genetic information that helps women and their clinicians …